Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Breast Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Breast Neoplasm

Cancer Family

Breast Neoplasm

CI-CAN-00000007Explore in graph →

Non-malignant2,894 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Overview
Statistics
Survival
Genomics33
Variants & evidence310
Drugs79
Trials13867
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
· Ann Oncol · 2020 · PMID 32348852 · validated civic_curation pubmed
Neurotrophic receptor tyrosine kinase (NTRK) fusions and their role in cancer.
· Cancer Cytopathol · 2020 · PMID 33002320 · validated civic_curation pubmed
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
· Cancer Discov · 2013 · PMID 23220880 · validated civic_curation pubmed
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
· Nat Genet · 2013 · PMID 24185510 · validated civic_curation pubmed
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
· Clin Cancer Res · 2011 · PMID 21558396 · validated civic_curation pubmed
The PI3K pathway as drug target in human cancer.
· J Clin Oncol · 2010 · PMID 20085938 · validated civic_curation pubmed
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
· Nature · 2015 · PMID 25409150 · validated civic_curation pubmed
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

Showing 201–225 of 268 publications

← Previous
1
…
8
9
10
11
Next →

· Cancer Cell · 2012 · PMID 22698404 · validated civic_curation pubmed

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

· Nature · 2016 · PMID 27279227 · validated civic_curation pubmed

Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.

· Mol Cancer Ther · 2016 · PMID 27297869 · validated civic_curation pubmed

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.

· Nat Commun · 2017 · PMID 28211448 · validated civic_curation pubmed

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

· Clin Cancer Res · 2010 · PMID 20453058 · validated civic_curation pubmed

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

· Cancer Res · 2008 · PMID 19010894 · validated civic_curation pubmed

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

· Clin Cancer Res · 2013 · PMID 23888070 · validated civic_curation pubmed

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

· Nat Genet · 2013 · PMID 24185512 · validated civic_curation pubmed

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

· Proc Natl Acad Sci U S A · 2005 · PMID 15647370 · validated civic_curation pubmed

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.Retracted

· PLoS One · 2008 · PMID 18725974 · validated civic_curation pubmed

Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.

· Mol Cancer Ther · 2014 · PMID 24356815 · validated civic_curation pubmed

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.

· Oncotarget · 2014 · PMID 25587029 · validated civic_curation pubmed

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

· Cell Cycle · 2015 · PMID 25590338 · validated civic_curation pubmed

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

· Cancer Res · 2008 · PMID 18593940 · validated civic_curation pubmed

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

· Oncogene · 2005 · PMID 16091755 · validated civic_curation pubmed

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

· Cancer Res · 2010 · PMID 20179196 · validated civic_curation pubmed

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

· Genes Dev · 2012 · PMID 22802530 · validated civic_curation pubmed

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

· Cancer Cell · 2004 · PMID 15324695 · validated civic_curation pubmed